{
 "cells": [
  {
   "cell_type": "markdown",
   "id": "99b951e2",
   "metadata": {},
   "source": [
    "# Entity Linking with RAG\n",
    "<br>\n",
    "James Chapman<br>\n",
    "CIS 830 Advanced Topics in AI – Term Project<br>\n",
    "Kansas State University<br><br>\n",
    "\n",
    "This notebook identifies EVERY DRUG MENTION (illicit/abusive) from list of 77 substances of interest.<br>\n",
    "\n",
    "- Uses 'rag_prompt'\n",
    "- Runs 4 LLMs (2 Paid Services & 2 Local HuggingFace Models)\n",
    "    - o4-mini \n",
    "    - GPT-4o-mini\n",
    "    - Meta-Llama-3.1-8B-Instruct\n",
    "    - Qwen-4B\n",
    "\n",
    "*** Saves response from every LLM call in separate text files."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "4e4579da",
   "metadata": {},
   "outputs": [],
   "source": [
    "import pandas as pd\n",
    "import numpy as np\n",
    "import matplotlib.pyplot as plt\n",
    "import seaborn as sns\n",
    "import json\n",
    "import os\n",
    "import re\n",
    "from tqdm import tqdm\n",
    "tqdm.pandas()\n",
    "\n",
    "from utils import (\n",
    "    get_tweets_dataset, \n",
    "    extract_responses,\n",
    "    extract_JSON_labels_and_explanations,\n",
    "    extract_drug_labels,\n",
    "    extract_RAG_drug_labels,\n",
    "    extract_T_F_labels, \n",
    "    match_terms,\n",
    "    get_confusion_matrix_and_metrics,\n",
    ")\n",
    "from llm_manager import (\n",
    "    run_prompt_on_llm,\n",
    "### paid #################\n",
    "    # get_claude_response, \n",
    "    # get_openai_response, \n",
    "    # get_perplexity_response,\n",
    "    get_openai_gpt4omini_response,\n",
    "    get_openai_o4mini_response,\n",
    "### local #################\n",
    "    get_llama_response, \n",
    "    get_qwen_4b_response,                        \n",
    "    #get_deepseek_qwen_response,\n",
    "    # get_qwen_response,\n",
    "    # get_mistral_response,\n",
    "    cleanup_llama,\n",
    "    cleanup_qwen,\n",
    "    cleanup_qwen_4b,\n",
    "    cleanup_deepseek_qwen,\n",
    "    cleanup_mistral,\n",
    ")\n",
    "\n",
    "# imports used for RAG retrievers \n",
    "from __future__ import annotations\n",
    "import logging\n",
    "logging.disable(level=logging.INFO)\n",
    "logger = logging.getLogger(__name__)\n",
    "logger.setLevel(logging.INFO)\n",
    "\n",
    "from concurrent.futures import ThreadPoolExecutor, as_completed\n",
    "from pathlib import Path\n",
    "from typing import List, Dict, Any, Optional, Tuple\n",
    "\n",
    "from langchain_core.documents import BaseDocumentCompressor, Document\n",
    "from langchain_community.document_loaders.csv_loader import CSVLoader\n",
    "from langchain_core.retrievers import BaseRetriever\n",
    "from langchain.chat_models import init_chat_model\n",
    "from langchain.prompts import PromptTemplate\n",
    "from langchain.docstore.document import Document as LangchainDocument\n",
    "from langchain.retrievers import BM25Retriever\n",
    "from langchain.vectorstores import FAISS\n",
    "from langchain_openai import OpenAIEmbeddings\n",
    "from langchain_community.document_loaders import WebBaseLoader, SeleniumURLLoader, TextLoader\n",
    "from langchain_text_splitters import RecursiveCharacterTextSplitter\n",
    "from langchain_cohere import CohereRerank\n",
    "from langchain.globals import set_llm_cache\n",
    "from langchain.cache    import SQLiteCache\n",
    "\n",
    "# Always save responses from LLMs to a local SQLite database\n",
    "set_llm_cache(SQLiteCache(database_path=\"data/llm_cache.sqlite\"))\n",
    "\n",
    "from dotenv import load_dotenv\n",
    "load_dotenv()\n",
    "\n",
    "# API keys\n",
    "os.environ[\"TOKENIZERS_PARALLELISM\"] = \"true\"\n",
    "os.environ[\"OPENAI_API_KEY\"]    = os.getenv('First_Key')\n",
    "os.environ[\"ANTHROPIC_API_KEY\"] = os.getenv('anthropic-first-key')\n",
    "os.environ[\"PPLX_API_KEY\"]      = os.getenv('perplexity-api-key')\n",
    "os.environ[\"COHERE_API_KEY\"]    = os.getenv('cohere-first-key')\n",
    "\n",
    "# models and embeddings\n",
    "model_name       = \"gpt-4.1-mini\" # \"gpt-4.1-mini\"gpt-4o-mini o4-mini gpt-4.1-nano\n",
    "model_provider   = \"openai\"\n",
    "embeddings_model = \"text-embedding-3-large\"\n",
    "llm        = init_chat_model(model_name, model_provider=model_provider)\n",
    "embeddings = OpenAIEmbeddings(model=embeddings_model)\n",
    "\n",
    "# constants\n",
    "MAX_WORKERS      = 28\n",
    "CONTEXT_WINDOW   = 1047576  # o4-mini tier 2"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 13,
   "id": "beb3eb63",
   "metadata": {},
   "outputs": [],
   "source": [
    "rag_prompt = \"\"\"\n",
    "### Role\n",
    "You moderate social‑media content for drug‑related references.\n",
    "\n",
    "### Tasks\n",
    "Given a post **and a set of RAG context chunks**:\n",
    "1. Detect every word or phrase (slang, euphemism, synonym, cultural references) that refers to an illicit drug or substance.\n",
    "   • Include illegal, RX, OTC, or recreational drugs (using, buying, promoting, encouraging or glorifying drug use).\n",
    "   • **Use the RAG chunks only as background knowledge for disambiguation; do NOT extract or return phrases that appear solely inside the chunks.**\n",
    "2. Link each detected phrase to its matching **Index Term** (see list below). \n",
    "   • If the drug is *not* in the list, use \"other\".\n",
    "3. Return **only** a valid JSON array, one object per match, using the schema  \n",
    "   `{\"index_term\": \"<Index Term or other>\", \"matched_phrase\": \"<exact text>\"}`.\n",
    "\n",
    "### Output: exact format\n",
    "[\n",
    "  {\"index_term\": \"Codeine\", \"matched_phrase\": \"lean\"},\n",
    "  {\"index_term\": \"Codeine\", \"matched_phrase\": \"codeine\"},\n",
    "  ...\n",
    "]    \n",
    "\n",
    "### Index Terms\n",
    "2,6-Xylidine (2,6-Dimethylaniline, 2‑amino‑1,3‑dimethylbenzene) – A toxic aniline derivative used as an intermediate in manufacturing local anesthetics and dyes.\n",
    "2‑Amino‑5‑chloropyridine (5‑Chloro‑2‑aminopyridine) – A breakdown product of the sleep drug zopiclone that serves as a urinary marker in drug tests.\n",
    "2‑Fluoro‑2‑oxo PCE (CanKet, 2F‑NENDCK, 2‑FXE) – A novel ketamine‑like dissociative anesthetic sold illicitly for its hallucinogenic effects.\n",
    "2‑Oxo‑3‑hydroxy‑LSD (2‑oxo‑3‑hydroxy lysergic acid diethylamide, oxo‑HO‑LSD) – The principal urinary metabolite of LSD produced after psychedelic use.\n",
    "3‑Hydroxy flubromazepam () – A primary metabolite of the designer benzodiazepine flubromazepam detectable in urine for an extended period.\n",
    "3‑Hydroxy flubromazepam glucuronide () – The glucuronidated form of 3‑hydroxy flubromazepam that aids bodily elimination of the parent drug.\n",
    "4‑ANPP (Despropionyl fentanyl, 4‑anilino‑N‑phenethylpiperidine) – A key precursor and metabolite of fentanyl often found as an impurity in illicit opioid production.\n",
    "4‑HIAA (4‑Hydroxyindole‑3‑acetic acid) – The main inactive metabolite excreted after psilocybin ingestion (“magic mushrooms”).\n",
    "6‑Acetylmorphine (6‑Monoacetylmorphine, 6‑MAM) – An active intermediate metabolite formed almost immediately after heroin use.\n",
    "7‑Aminoclonazepam () – The chief urinary metabolite of the prescription benzodiazepine clonazepam.\n",
    "7‑Hydroxymitragynine (7‑OH‑Mitragynine) – A potent kratom alkaloid and human metabolite that produces strong opioid‑like effects.\n",
    "7‑OH‑CBD glucuronide () – A conjugated metabolite formed during cannabidiol (CBD) metabolism and excreted in urine.\n",
    "8‑Aminoclonazolam () – A metabolite indicating use of the designer benzodiazepine clonazolam in toxicology screens.\n",
    "8R‑OH‑R‑HHC (8α‑hydroxy‑9β‑HHC) – A hydroxylated metabolite of the synthetic cannabinoid HHC produced during metabolism.\n",
    "8S‑OH‑R‑HHC (8β‑hydroxy‑9β‑HHC) – The epimeric hydroxylated metabolite of R‑HHC likewise formed in users of HHC products.\n",
    "α‑Hydroxyalprazolam (α‑OH‑alprazolam) – The major active metabolite of alprazolam (Xanax) contributing to its sedative effects.\n",
    "α‑Hydroxybromazolam (α‑OH‑bromazolam) – An oxidative metabolite used to confirm bromazolam ingestion.\n",
    "Amphetamine (Speed, Bennies, Adderall) – A central nervous system stimulant prescribed for ADHD that is frequently abused for euphoria and wakefulness.\n",
    "Benzoylecgonine (BZE, Ecgonine benzoate) – The primary metabolite of cocaine measured in urine drug testing.\n",
    "Bromazolam (XLI‑268, Fake Xanax) – A designer benzodiazepine sold illicitly that mimics the sedative effects of alprazolam.\n",
    "Buprenorphine (Suboxone, Subutex, Bupe) – A partial opioid agonist used to treat opioid dependence and moderate pain with a ceiling on respiratory depression.\n",
    "Carfentanil (Wildnil, Elephant tranquilizer) – An ultra‑potent fentanyl analog used for large‑animal sedation and deadly in microgram doses to humans.\n",
    "CBD (Cannabidiol, Epidiolex) – A non‑intoxicating cannabinoid with antiepileptic and anxiolytic properties approved for certain seizure disorders.\n",
    "Codeine (Lean, Purple Drank, Schoolboy) – A mild opioid painkiller and cough suppressant that is widely abused in syrup form for euphoric “lean.”\n",
    "Cyclobenzaprine (Flexeril, Amrix, Fexmid) – A muscle relaxant related to tricyclic antidepressants used for short‑term relief of muscle spasms.\n",
    "delta‑8‑THC‑COOH (11‑nor‑9‑carboxy‑delta‑8‑THC) – The main inactive urinary metabolite indicating use of delta‑8‑THC products.\n",
    "delta‑9‑THC‑COOH (11‑nor‑9‑carboxy‑THC, THC‑COOH) – The principal inactive metabolite of cannabis’ delta‑9‑THC detected in urine screens.\n",
    "Diphenhydramine (Benadryl, Nytol) – A first‑generation antihistamine with sedative and anticholinergic effects that is sometimes misused at high doses.\n",
    "EDDP () – The inactive metabolite of methadone used to verify methadone compliance in treatment programs.\n",
    "Fentanyl (China White, Apache, Duragesic) – A synthetic opioid 50–100 times stronger than morphine that drives many overdose deaths.\n",
    "Flubromazepam () – A long‑acting “research chemical” benzodiazepine producing prolonged sedation and anxiolysis.\n",
    "Gabapentin (Neurontin, Gralise, Gabbies) – An anticonvulsant prescribed for neuropathic pain and seizures that carries some abuse potential.\n",
    "Hydrocodone (Vicodin, Norco, Vike) – A commonly prescribed semi‑synthetic opioid painkiller frequently diverted for nonmedical use.\n",
    "Hydromorphone (Dilaudid, Dillies) – A potent morphine derivative used for severe pain with rapid onset and high addiction risk.\n",
    "Ketamine (Special K, Keta, Ketalar) – A dissociative anesthetic causing trance‑like analgesia and hallucinations prized both medically and recreationally.\n",
    "Lorazepam (Ativan) – A short‑acting benzodiazepine anxiolytic used for anxiety, insomnia, and seizure emergencies.\n",
    "LSD (Acid, Lucy, Delysid) – A potent psychedelic that dramatically alters perception and cognition at microgram doses.\n",
    "Marijuana (Cannabis, Weed, Pot) – The most widely used illicit drug, containing psychoactive cannabinoids THC only.\n",
    "MDA (Sass, Love Drug, 3,4‑methylenedioxyamphetamine) – An entactogenic and psychedelic stimulant similar to MDMA but with stronger visuals.\n",
    "MDMA (Ecstasy, Molly, 3,4‑methylenedioxymethamphetamine) – A popular club drug producing euphoria, empathy, and heightened sensory perception.\n",
    "MDMB‑4en‑PINACA butanoic acid () – A primary metabolite confirming use of the potent synthetic cannabinoid MDMB‑4en‑PINACA.\n",
    "Meperidine (Demerol, Pethidine) – A synthetic opioid analgesic now rarely used due to its toxic metabolite normeperidine.\n",
    "Meprobamate (Miltown, Equanil) – A historical anxiolytic “tranquilizer” that produces barbiturate‑like sedation and dependency risk.\n",
    "Methadone (Dolophine, Methadose, Done) – A long‑acting opioid agonist employed in maintenance therapy and chronic pain management.\n",
    "Methamphetamine (Crystal Meth, Ice, Desoxyn) – A powerful stimulant drug with high addiction potential and neurotoxic effects when abused.\n",
    "Metonitazene () – A nitazene‑class synthetic opioid comparable in potency to fentanyl and implicated in recent overdose clusters.\n",
    "Mitragynine () – The main kratom alkaloid acting as a partial opioid receptor agonist with stimulant properties at low doses.\n",
    "Morphine (MS Contin, Miss Emma, Morph) – The prototypical opioid analgesic used for severe pain but prone to tolerance and dependence.\n",
    "N,N‑Dimethylpentylone () – A novel synthetic cathinone stimulant (“bath salt”) producing amphetamine‑like sympathomimetic effects.\n",
    "Naltrexone (Vivitrol, Revia) – An opioid antagonist medication that blocks opioid and alcohol effects to support abstinence.\n",
    "N‑Desethylmetonitazene () – A potent nitazene opioid analog/metabolite contributing to toxicity in illicit opioid samples.\n",
    "Norbuprenorphine () – The primary active metabolite of buprenorphine with limited brain penetration and peripheral opioid effects.\n",
    "Norcarfentanil () – The main metabolite of carfentanil detected in biological samples after exposure to the parent ultra‑potent opioid.\n",
    "Nordiazepam (Desmethyldiazepam, Nordazepam) – A long‑acting active metabolite of diazepam that extends benzodiazepine sedation.\n",
    "Norfentanyl () – The principal inactive metabolite of fentanyl used as a biomarker of fentanyl intake.\n",
    "Norketamine () – The chief metabolite of ketamine that retains mild anesthetic and analgesic activity.\n",
    "Normeperidine (Norpethidine) – A neurotoxic excitatory metabolite of meperidine that can cause seizures at high concentrations.\n",
    "Noroxycodone () – An inactive N‑demethylated metabolite of oxycodone excreted renally.\n",
    "N‑Pyrrolidinoetonitazene () – An emerging nitazene synthetic opioid of extreme potency implicated in fatal overdoses.\n",
    "O‑Desmethyltramadol (O‑DSMT) – The active metabolite of tramadol with significantly stronger μ‑opioid receptor activity than the parent drug.\n",
    "ortho‑Methylfentanyl (2‑Methylfentanyl) – A highly potent clandestine fentanyl analog historically known as “China White.”\n",
    "Oxazepam (Serax) – A short‑to‑intermediate‑acting benzodiazepine used for anxiety and alcohol withdrawal.\n",
    "Oxycodone (OxyContin, Percocet, Hillbilly Heroin) – A semi‑synthetic opioid widely prescribed for pain and heavily misused for its heroin‑like high.\n",
    "Oxymorphone (Opana) – A very potent opioid analgesic withdrawn from U.S. markets due to abuse of its extended‑release form.\n",
    "para‑Fluorofentanyl (p‑Fluorofentanyl) – A fentanyl analog with comparable potency that has surfaced in illicit opioid mixtures.\n",
    "para‑Fluoronorfentanyl () – The N‑dealkylated metabolite of para‑fluorofentanyl used to confirm exposure to the parent analog.\n",
    "Pentylone (bk‑MBDP, βk‑Methylbenzodioxylpentanamine) – A synthetic cathinone stimulant producing euphoria and increased energy similar to methylone.\n",
    "Phencyclidine (PCP, Angel Dust, Sherm) – A dissociative anesthetic that causes hallucinations, detachment, and unpredictable behavior.\n",
    "Pregabalin (Lyrica) – An anticonvulsant and anxiolytic agent used for neuropathic pain and prone to misuse for its calming effects.\n",
    "Psilocin (4‑HO‑DMT) – The psychoactive metabolite of psilocybin responsible for the hallucinations of “magic mushrooms.”\n",
    "Psilocybin (4‑PO‑DMT) – A natural prodrug compound in psychedelic mushrooms that converts to psilocin to produce its effects.\n",
    "R‑HHC‑COOH () – The carboxylic acid metabolite of the R‑enantiomer of hexahydrocannabinol excreted after HHC use.\n",
    "S‑HHC‑COOH () – The carboxylic acid metabolite of the S‑enantiomer of hexahydrocannabinol excreted after HHC use.\n",
    "Speciociliatine () – A minor kratom alkaloid with weak opioid activity contributing modestly to the plant’s overall effects.\n",
    "Temazepam (Restoril, Jellies) – A benzodiazepine hypnotic taken for short‑term insomnia and sometimes abused for its strong sedation.\n",
    "Xylazine (Tranq, Rompun) – A veterinary sedative increasingly found as a street‑drug adulterant causing deep sedation and severe skin ulcers.\n",
    "Zolpidem (Ambien, Stilnox) – A short‑acting non‑benzodiazepine hypnotic prescribed for insomnia that can cause complex sleep behaviors.\n",
    "Zopiclone (Imovane) – A non‑benzodiazepine sleep aid used to treat insomnia, known for metallic after‑taste and next‑day drowsiness.\n",
    "\n",
    "### BEGINNING of RAG Chunks  \n",
    "{{rag_chunks}}\n",
    "### ENDING of RAG Chunks\n",
    "\n",
    "### Example #1 \n",
    "Post: I got her hooked on that lean everyday she say she want codeine\n",
    "[{\"index_term\": \"Codeine\", \"matched_phrase\": \"lean\"}, {\"index_term\": \"Codeine\", \"matched_phrase\": \"codeine\"}]\n",
    "\n",
    "### Example #2 \n",
    "Post: Pulled an all‑nighter on addy again.\n",
    "[{\"index_term\": \"Amphetamine\", \"matched_phrase\": \"addy\"}]\n",
    "\n",
    "### Example #3\n",
    "Post: Popped two xans before class.\n",
    "[{\"index_term\": \"other\", \"matched_phrase\": \"xans\"}]\n",
    "\n",
    "### Example #4 (Cocaine not on the list)\n",
    "Post: Picked up fresh snow to ride those white lines tonight ❄️\n",
    "[{\"index_term\": \"other\", \"matched_phrase\": \"snow\"}, {\"index_term\": \"other\", \"matched_phrase\": \"white lines\"}]\n",
    "\n",
    "Post: {{tweet_text}}\n",
    "\"\"\"\n"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "8ea102fe",
   "metadata": {},
   "source": [
    "# Load Chunks \n",
    "- created from '1 - rag_retriever.ipynb' "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "id": "39fdac6c",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Loaded 9,695 chunks \n",
      "Loaded 9,695 contextual chunks from 439 files.\n"
     ]
    }
   ],
   "source": [
    "DATA_CHUNKS_DIR = Path(\"data/chunks2\")\n",
    "chunks: list[Document] = []\n",
    "with Path(\"data/chunks2.jsonl\").open(\"r\", encoding=\"utf-8-sig\") as f:\n",
    "    for line in f:\n",
    "        obj = json.loads(line)\n",
    "        chunks.append(\n",
    "            Document(\n",
    "                page_content=obj[\"content\"],\n",
    "                metadata=obj[\"metadata\"],\n",
    "            )\n",
    "        )\n",
    "print(f\"Loaded {len(chunks):,} chunks \")\n",
    "\n",
    "contextual_chunks = []\n",
    "DATA_CHUNKS_DIR = Path(\"data/contextual_chunks2\")\n",
    "for fpath in sorted(\n",
    "        DATA_CHUNKS_DIR.glob(\"*.jsonl\"),\n",
    "        key=lambda p: int(p.stem) if p.stem.isdigit() else p.stem\n",
    "):\n",
    "    with fpath.open(encoding=\"utf-8-sig\") as f:\n",
    "        for line in f:\n",
    "            record = json.loads(line)\n",
    "            contextual_chunks.append(\n",
    "                Document(\n",
    "                    page_content=record[\"content\"],\n",
    "                    metadata=record[\"metadata\"],\n",
    "                )\n",
    "            )\n",
    "\n",
    "print(f\"Loaded {len(contextual_chunks):,} contextual chunks \"\n",
    "      f\"from {len(list(DATA_CHUNKS_DIR.glob('*.jsonl')))} files.\")\n"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "f91d1226",
   "metadata": {},
   "source": [
    "# Create Retrievers from chunks\n",
    "- 6 retrievers (currently only using 1)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "id": "8653172a",
   "metadata": {},
   "outputs": [],
   "source": [
    "\n",
    "# We now have 2 kinds of chunks: 'vanilla' and 'contextualized'\n",
    "# Create 3 types of retrievers: (for each type of chunking)\n",
    "#       'embedding', \n",
    "#       'bm25',  \n",
    "#       'combination' = embedding + bm25 + reranker\n",
    "\n",
    "######  reranker  ##############################################################\n",
    "reranker = CohereRerank(top_n=3, model=\"rerank-english-v3.0\") #\"rerank-english-v2.0\")\n",
    "################################################################################\n",
    "#\n",
    "def create_embedding_retriever(documents_):\n",
    "    vector_store = FAISS.from_documents(documents_, embedding=embeddings)\n",
    "    return vector_store.as_retriever(search_kwargs={\"k\": 4})\n",
    "\n",
    "def batch_embed_texts(texts, embedding_model, chunk_size=100):\n",
    "    all_embeddings = []\n",
    "    for i in range(0, len(texts), chunk_size):\n",
    "        batch = texts[i:i + chunk_size]\n",
    "        all_embeddings.extend(embedding_model.embed_documents(batch))\n",
    "    return all_embeddings\n",
    "\n",
    "def batch_create_embedding_retriever(documents_):\n",
    "    texts = [doc.page_content for doc in documents_]\n",
    "    metadatas = [doc.metadata for doc in documents_]\n",
    "\n",
    "    # Safe batching to avoid max token limits\n",
    "    embeddings_list = batch_embed_texts(texts, embeddings, chunk_size=100)\n",
    "\n",
    "    text_embedding_pairs = zip(texts, embeddings_list)\n",
    "\n",
    "    return FAISS.from_embeddings(text_embeddings=text_embedding_pairs, embedding=embeddings, metadatas=metadatas).as_retriever(search_kwargs={\"k\": 4})\n",
    "\n",
    "\n",
    "def create_bm25_retriever(documents_):\n",
    "    retriever = BM25Retriever.from_documents(documents_, language=\"english\")\n",
    "    return retriever\n",
    "\n",
    "# Function to create a combined retriever: embedding + BM25 + reranker\n",
    "class EmbeddingBM25RerankerRetriever:\n",
    "    def __init__(\n",
    "        self,\n",
    "        vector_retriever: BaseRetriever,\n",
    "        bm25_retriever: BaseRetriever,\n",
    "        reranker: BaseDocumentCompressor,\n",
    "    ):\n",
    "        self.vector_retriever = vector_retriever\n",
    "        self.bm25_retriever = bm25_retriever\n",
    "        self.reranker = reranker\n",
    "\n",
    "    def invoke(self, query: str):\n",
    "        vector_docs = self.vector_retriever.invoke(query)\n",
    "        bm25_docs = self.bm25_retriever.invoke(query)\n",
    "\n",
    "        combined_docs = vector_docs + [\n",
    "            doc for doc in bm25_docs if doc not in vector_docs\n",
    "        ]\n",
    "\n",
    "        reranked_docs = self.reranker.compress_documents(combined_docs, query)\n",
    "        return reranked_docs\n",
    "    \n",
    "##################################################################################\n",
    "# vanilla chunks\n",
    "##################################################################################\n",
    "\n",
    "embedding_retriever = create_embedding_retriever(chunks)\n",
    "\n",
    "bm25_retriever = create_bm25_retriever(chunks)\n",
    "\n",
    "embedding_bm25_retriever_rerank = EmbeddingBM25RerankerRetriever(\n",
    "    vector_retriever=embedding_retriever,\n",
    "    bm25_retriever=bm25_retriever,\n",
    "    reranker=reranker,\n",
    ")\n",
    "\n",
    "##################################################################################\n",
    "# contextualized chunks\n",
    "##################################################################################\n",
    "\n",
    "contextual_embedding_retriever = batch_create_embedding_retriever(contextual_chunks)\n",
    "\n",
    "contextual_bm25_retriever = create_bm25_retriever(contextual_chunks)\n",
    "\n",
    "contextual_embedding_bm25_retriever_rerank = EmbeddingBM25RerankerRetriever(\n",
    "    vector_retriever=contextual_embedding_retriever,\n",
    "    bm25_retriever=contextual_bm25_retriever,\n",
    "    reranker=reranker,\n",
    ")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "id": "c2f8bb3f",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "<class 'pandas.core.frame.DataFrame'>\n",
      "RangeIndex: 1000 entries, 0 to 999\n",
      "Data columns (total 13 columns):\n",
      " #   Column                     Non-Null Count  Dtype \n",
      "---  ------                     --------------  ----- \n",
      " 0   text                       1000 non-null   object\n",
      " 1   label                      1000 non-null   object\n",
      " 2   tweet_num                  1000 non-null   int64 \n",
      " 3   found_terms                1000 non-null   object\n",
      " 4   found_index_terms          1000 non-null   object\n",
      " 5   GPT_found_terms            1000 non-null   object\n",
      " 6   GPT_found_index_terms      1000 non-null   object\n",
      " 7   pubchem_found_terms        1000 non-null   object\n",
      " 8   pubchem_found_index_terms  1000 non-null   object\n",
      " 9   redmed_found_terms         1000 non-null   object\n",
      " 10  redmed_found_index_terms   1000 non-null   object\n",
      " 11  DEA_found_terms            1000 non-null   object\n",
      " 12  DEA_found_index_terms      1000 non-null   object\n",
      "dtypes: int64(1), object(12)\n",
      "memory usage: 101.7+ KB\n"
     ]
    }
   ],
   "source": [
    "tweets = get_tweets_dataset()\n",
    "SEED = 777\n",
    "tweets = ( tweets.sample(n=1_000, random_state=SEED, replace=False)\n",
    "                 .sort_index()\n",
    "                 .reset_index(drop=True)\n",
    ")\n",
    "tweets.info(verbose=True)"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "d1af673e",
   "metadata": {},
   "source": [
    "# Run retriever on tweets\n",
    "- For every tweet, gather 3 most relevant chunks (each chunk will have relevance score)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "ef3334cd",
   "metadata": {},
   "outputs": [],
   "source": [
    "def run_retriever_on_tweets(retriever, directory, tweets):\n",
    "    os.makedirs(f\"data/{directory}\", exist_ok=True)\n",
    "    all_retrieved_chunks = []\n",
    "    for i, row in tqdm(tweets.iterrows(), total=tweets.shape[0]):                          \n",
    "        text = row[\"text\"]\n",
    "        retrieved_chunks = retriever.invoke(text)\n",
    "        all_retrieved_chunks.extend(retrieved_chunks)\n",
    "        with open(f\"data/{directory}/{i}.txt\", \"w\", encoding=\"utf-8-sig\") as f:\n",
    "            for chunk in retrieved_chunks:\n",
    "                json.dump(\n",
    "                    {\n",
    "                        \"metadata\": chunk.metadata,\n",
    "                        \"content\":  chunk.page_content,\n",
    "                    },\n",
    "                    f,\n",
    "                    ensure_ascii=False,\n",
    "                    default=str,\n",
    "                )\n",
    "                f.write(\"\\n\")\n",
    "    return \n",
    "# run once\n",
    "run_retriever_on_tweets(contextual_embedding_bm25_retriever_rerank, 'retrieved_chunks__contextual_rerank', tweets)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "id": "aee691b8",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "1000\n"
     ]
    }
   ],
   "source": [
    "def load_retrieved_chunks(directory):\n",
    "    all_retrieved_chunks: List[Document] = []\n",
    "    for i in range(tweets.shape[0]):       \n",
    "        retrieved_chunks: List[Document] = []\n",
    "        with open(f\"data/{directory}/{i}.txt\", \"r\", encoding=\"utf-8-sig\") as f:\n",
    "            for line in f:\n",
    "                obj = json.loads(line)\n",
    "                retrieved_chunks.append(\n",
    "                    Document(\n",
    "                        page_content=obj[\"content\"],\n",
    "                        metadata=obj[\"metadata\"],\n",
    "                    )\n",
    "                )\n",
    "        all_retrieved_chunks.append(retrieved_chunks)\n",
    "    return all_retrieved_chunks\n",
    "all_retrieved_chunks = load_retrieved_chunks(\"retrieved_chunks__contextual_rerank\")\n",
    "\n",
    "all_relevance_scores = []\n",
    "for ret_chunks in all_retrieved_chunks:\n",
    "    one_tweet_relevance_scores = []\n",
    "    for c in ret_chunks:\n",
    "        one_tweet_relevance_scores.append(c.metadata['relevance_score'])\n",
    "    all_relevance_scores.append(one_tweet_relevance_scores)\n",
    "    \n",
    "print(len(all_retrieved_chunks))"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "bff5c898",
   "metadata": {},
   "source": [
    "# Analyze Retrieved Chunks\n",
    "- Inspect relevance scores\n",
    "- Inspect relevance score distributions & for each tweet\n",
    "- Determine relevance score threshold (used to determine if the chunks will be used in the prompt)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "459ce397",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Relevance Score</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>count</th>\n",
       "      <td>3.000000e+03</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>mean</th>\n",
       "      <td>2.333519e-02</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>std</th>\n",
       "      <td>1.265687e-01</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>min</th>\n",
       "      <td>3.028843e-08</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1%</th>\n",
       "      <td>3.950356e-08</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5%</th>\n",
       "      <td>6.412061e-08</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10%</th>\n",
       "      <td>1.226339e-07</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>25%</th>\n",
       "      <td>6.179393e-07</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>50%</th>\n",
       "      <td>9.295810e-06</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>75%</th>\n",
       "      <td>1.944937e-04</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>90%</th>\n",
       "      <td>4.487542e-03</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>95%</th>\n",
       "      <td>3.824018e-02</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>99%</th>\n",
       "      <td>9.460150e-01</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>max</th>\n",
       "      <td>9.999729e-01</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "       Relevance Score\n",
       "count     3.000000e+03\n",
       "mean      2.333519e-02\n",
       "std       1.265687e-01\n",
       "min       3.028843e-08\n",
       "1%        3.950356e-08\n",
       "5%        6.412061e-08\n",
       "10%       1.226339e-07\n",
       "25%       6.179393e-07\n",
       "50%       9.295810e-06\n",
       "75%       1.944937e-04\n",
       "90%       4.487542e-03\n",
       "95%       3.824018e-02\n",
       "99%       9.460150e-01\n",
       "max       9.999729e-01"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "# all_retrieved_chunks : List[List[Document]]\n",
    "# one inner list per tweet, 3 chunks per list\n",
    "all_relevance_scores = []          # shape → 1000 × 3\n",
    "flat_scores          = []          # shape → 3000\n",
    "\n",
    "for tweet_chunks in all_retrieved_chunks:\n",
    "    scores = [c.metadata.get(\"relevance_score\", 0.0)\n",
    "              for c in tweet_chunks]\n",
    "    all_relevance_scores.append(scores)\n",
    "    flat_scores.extend(scores)\n",
    "\n",
    "scores = np.array(flat_scores)\n",
    "tweet_df = pd.DataFrame(all_relevance_scores,\n",
    "                        columns=[f\"chunk_{i}\" for i in range(1, 4)])\n",
    "tweet_df[\"tweet_max\"]   = tweet_df.max(axis=1)\n",
    "tweet_df[\"tweet_mean\"]  = tweet_df.mean(axis=1)\n",
    "tweet_df[\"tweet_stdev\"] = tweet_df.std(axis=1)\n",
    "\n",
    "summary = pd.Series(scores).describe(percentiles=[.01,.05,.10,.25,.5,.75,.90,.95,.99])\n",
    "display(summary.to_frame(\"Relevance Score\"))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "id": "7216e46d",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 640x480 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 640x480 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 1000x400 with 2 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "\n",
    "plt.figure()\n",
    "plt.hist(scores, bins=50)\n",
    "plt.title(\"Distribution of all 3 000 relevance scores\")\n",
    "plt.xlabel(\"relevance_score\")\n",
    "plt.ylabel(\"count\")\n",
    "plt.show()\n",
    "\n",
    "plt.figure()\n",
    "plt.hist(tweet_df[\"tweet_max\"], bins=50)\n",
    "plt.title(\"Distribution of max score per tweet (1000 values)\")\n",
    "plt.xlabel(\"max relevance_score\")\n",
    "plt.ylabel(\"count\")\n",
    "plt.show()\n",
    "\n",
    "fig, ax = plt.subplots(1, 2, figsize=(10,4))\n",
    "sns.boxplot(y=scores, ax=ax[0]);           ax[0].set_title(\"Boxplot of all scores\")\n",
    "sns.violinplot(y=scores, ax=ax[1]);        ax[1].set_title(\"Violin plot of all scores\")\n",
    "plt.show()\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "id": "54be2a79",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Chunks with relevance_score < 0.05 : 2,862 / 3000\n",
      "Tweets where max(chunk) < 0.05     : 939 / 1000\n",
      "Chunks with relevance_score < 0.2 : 2,904 / 3000\n",
      "Tweets where max(chunk) < 0.2     : 960 / 1000\n",
      "Chunks with relevance_score < 0.5 : 2,941 / 3000\n",
      "Tweets where max(chunk) < 0.5     : 974 / 1000\n"
     ]
    }
   ],
   "source": [
    "threshold = 0.05\n",
    "\n",
    "n_chunks_below = int((scores < threshold).sum())\n",
    "print(f\"Chunks with relevance_score < {threshold} : {n_chunks_below:,} / {scores.size}\")\n",
    "\n",
    "n_tweets_all_below = int((tweet_df.max(axis=1) < threshold).sum())\n",
    "print(f\"Tweets where max(chunk) < {threshold}     : {n_tweets_all_below:,} / {len(tweet_df)}\")\n",
    "\n",
    "\n",
    "\n",
    "threshold = 0.2\n",
    "\n",
    "n_chunks_below = int((scores < threshold).sum())\n",
    "print(f\"Chunks with relevance_score < {threshold} : {n_chunks_below:,} / {scores.size}\")\n",
    "\n",
    "n_tweets_all_below = int((tweet_df.max(axis=1) < threshold).sum())\n",
    "print(f\"Tweets where max(chunk) < {threshold}     : {n_tweets_all_below:,} / {len(tweet_df)}\")\n",
    "\n",
    "\n",
    "threshold = 0.5\n",
    "\n",
    "n_chunks_below = int((scores < threshold).sum())\n",
    "print(f\"Chunks with relevance_score < {threshold} : {n_chunks_below:,} / {scores.size}\")\n",
    "\n",
    "n_tweets_all_below = int((tweet_df.max(axis=1) < threshold).sum())\n",
    "print(f\"Tweets where max(chunk) < {threshold}     : {n_tweets_all_below:,} / {len(tweet_df)}\")\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "id": "a60846e6",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Tweet   65  |  Chunk 0  |  score=0.0455\n",
      "--------------------------------------------------------------------------------\n",
      "Drug: Codeine | cid: 5284371 Source: psychonaut | Source description: Codeine (also known as 3-Methylmorphine) is a naturally-occurring opioid substance of the morphinan class found in extracts of the poppy, particularly Papaver bracteatum.[3] Members of this group produce effects such as sedation, cough suppression, and euphoria when administered.                      Text:                      Erowid Experience Vaults: Codeine  Common forms  Codeine is available within pharmacies across the world in a variety of forms that combine it with other products that are dangerous or even fatal to consume at higher dosages. This is done to act as a deterrent to prevent their recreational use but can easily be circumvented with the use of a cold water extraction.    Co-codamol contain 500mg of paracetamol per 8mg of codeine. It is available behind the counter in any British pharmacy.    Nurofen plus contain 12.8mg of codeine alongside ibuprofen. It is available behind the counter in any British pharmacy. Due to the higher codeine content than co-codamol, they are better for cold water extraction.    Many prescription-strength cough syrups contain codeine and promethazine - an antihistamine. When used recreationally they are commonly known as lean or purple drank.  Toxicity and harm potential                       Context:                      This section details the common forms and preparations of codeine available worldwide, including over-the-counter medications like co-codamol and Nurofen Plus, as well as prescription cough syrups mixed with promethazine. It emphasizes the potential dangers of combining these formulations at high doses and provides insight into their recreational use and associated risks, complementing the broader discussion of codeine's effects, toxicity, and harm potential.                  …\n",
      "\n",
      "Tweet   66  |  Chunk 0  |  score=0.0418\n",
      "--------------------------------------------------------------------------------\n",
      "Drug: Codeine | cid: 5284371 Source: erowid | Source description: Information about Codeine including uses, images, dosage, effects, legal status, and links to other resources. Erowid name: codeine Category: PHARMS Field: MainPage                      Text:                      What is in the \"cough syrup\" that is associated with hip-h...  EXPERIENCES #  Peace in the Valley, by The Miles Away Girl  Good Buzz When I'm Broke, by The Günter Unit  What a Beautiful Drug It Is, by Anonymo the Wise  First Time Trial , by zophen  Seeds of Addiction, by Noz  » » » MORE » » »  OFF-SITE RESOURCES  SECONDARY RESOURCES #  Codeine Information [archive.org snapshot]  RxList : Codeine with Acetaminophen  RxMed : Tylenol with codeine  [ back to pharms ]  Created by Erowid - Unknown Modified - May 10, 2016  Content & design © 1995-2023 Erowid.org. Permission required before publicly reproducing Erowid info.                       Context:                      This chunk is part of the Codeine drug page on Erowid, highlighting user experience reports related to codeine, including personal testimonials such as \"Peace in the Valley\" and \"Seeds of Addiction.\" It also provides links to external resources like archive.org, RxList, and RxMed for additional information. This section is relevant for understanding anecdotal effects and accessing further technical or medical details about codeine.                  …\n",
      "\n",
      "Tweet   66  |  Chunk 1  |  score=0.0362\n",
      "--------------------------------------------------------------------------------\n",
      "Drug: Codeine | cid: 5284371 Source: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.                      Text:                      UNII-Q830PW7520  N-methyl norcodine  (4R,4aR,7S,7aR,12bS)-9-methoxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7-ol  Codeine [INN:BAN]  CODEINE MONOHYDRATE (EP MONOGRAPH)  3-o-methylmorphine monohydrate  DIHYDROCODEINE HYDROGEN TARTRATE IMPURITY A (EP IMPURITY)  DIHYDROCODEINE HYDROGEN TARTRATE IMPURITY A [EP IMPURITY]  HYDROCODONE HYDROGEN TARTRATE 2.5-HYDRATE IMPURITY C (EP IMPURITY)  HYDROCODONE HYDROGEN TARTRATE 2.5-HYDRATE IMPURITY C [EP IMPURITY]  (Codeine)  Morphinan-6-ol, 7,8-didehydro-4,5-epoxy-3-methoxy-17-methyl-, (5.alpha.,6.alpha.)-  (1S,13R,14S,17R)-10-methoxy-4-methyl-12-oxa-4-azapentacyclo(9.6.1.0(1,13).0(5,17).0(7,18))octadeca-7(18),8,10,15-tetraen-14-ol  (1S,13R,14S,17R)-10-methoxy-4-methyl-12-oxa-4-azapentacyclo[9.6.1.0(1,13).0(5,17).0(7,18)]octadeca-7(18),8,10,15-tetraen-14-ol  10-methoxy-4-methyl-(1S,5R,13R,14S,17R)-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraen-14-ol(Codeine)                       Context:                      This chunk provides detailed chemical identifiers, alternative names, and impurity descriptions for codeine-related compounds, including the UNII code Q830PW7520 and various chemical synonyms and impurities, situating it within the comprehensive chemical and pharmacological data presented in the full webpage. It is relevant for precise search retrieval of chemical structures, impurities, and regulatory identifiers related to codeine.                  …\n",
      "\n",
      "Tweet   66  |  Chunk 2  |  score=0.0342\n",
      "--------------------------------------------------------------------------------\n",
      "Drug: Codeine | cid: 5284371 Source: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.                      Text:                      Property Name  Hydrogen Bond Acceptor Count  Property Value  Reference  Computed by Cactvs 3.4.8.18 (PubChem release 2024.11.20)  Property Name  Rotatable Bond Count  Property Value  Reference  Computed by Cactvs 3.4.8.18 (PubChem release 2024.11.20)  Property Name  Exact Mass  Property Value  299.15214353 Da  Reference  Computed by PubChem 2.2 (PubChem release 2024.11.20)  Property Name  Monoisotopic Mass  Property Value  299.15214353 Da  Reference  Computed by PubChem 2.2 (PubChem release 2024.11.20)  Property Name  Topological Polar Surface Area  Property Value  41.9 Å²  Reference  Computed by Cactvs 3.4.8.18 (PubChem release 2024.11.20)  Property Name  Heavy Atom Count  Property Value  22  Reference  Computed by PubChem  Property Name  Formal Charge  Property Value  Reference  Computed by PubChem  Property Name  Complexity  Property Value  509  Reference  Computed by Cactvs 3.4.8.18 (PubChem release 2024.11.20)  Property Name  Isotope Atom Count  Property Value  Reference                       Context:                      This section provides key computed molecular properties of codeine, such as hydrogen bond acceptor count, rotatable bonds, exact and monoisotopic mass, topological polar surface area, heavy atom count, formal charge, complexity, and isotope atom count. These details are crucial for chemical identification and characterization, fitting into the overall PubChem compound profile which consolidates chemical, physical, and pharmacological data for search retrieval and research purposes.                  …\n",
      "\n",
      "Tweet  128  |  Chunk 2  |  score=0.0299\n",
      "--------------------------------------------------------------------------------\n",
      "Drug: Codeine | cid: 5284371 Source: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.                      Text:                      centered on access via family medicine cabinets, prescribers and pharmacies. Discussion and dissemination of indigenous harm reduction tactics included the learning to appreciate codeine's effect via moderated use in optimal settings, avoidance of tolerance by use of informed dosing schedules, cold water extraction of codeine, and using codeine as an alternative to stronger opioids. Oral and rectal routes were favored, with awareness on forums of the harms of intravenous and subcutaneous injection. 250 mg was recommended to optimize recreational outcomes. Forum users describe potentiating practices and using over-the-counter medications to improve intoxication experiences and reduce unpleasant side effects. Dissociative effects, ability to ignore physical and emotional pain, codeine-induced synesthesia and altered states of consciousness were described. Overdose was characterized by anesthesia, severe chest and stomach pain, respiratory depression, panic and fear of death. Efforts to                       Context:                      This excerpt details user-reported harm reduction strategies and effects related to recreational codeine use, emphasizing methods such as moderation, extraction, and route preferences, alongside descriptions of intoxication experiences and overdose symptoms. It situates within the comprehensive webpage on codeine, highlighting both social practices and risks associated with non-medical use, relevant for toxicity, pharmacology, and abuse literature. Its focus on user discourse and harm minimization complements the scientific and safety information provided elsewhere in the document.                  …\n",
      "\n",
      "Tweet  160  |  Chunk 0  |  score=0.0394\n",
      "--------------------------------------------------------------------------------\n",
      "Drug: Oxycodone | cid: 5284603 Source: erowid | Source description: A summary of basic information about Oxycodone (Percocet, Oxycontin) and its use. Erowid name: oxycodone Category: PHARMS Field: Basics                      Text:                      those hypersensitive to opiates  history of drug or alcohol abuse  those with head injuries, increased intracranial pressure, seizures, asthma, COPD, prostatic hyperplassia, severe hepatic or renal disease, acute abdominal conditions, urethral stricture, hypothyroidism, Addison's disease, or arrhythmias  Addiction Potential #  Oxycodone is both physically and psychologically addicting. Anyone taking it, whether for recreational or medicinal reasons, may become addicted, especially if it is used on a daily basis. Tolerance is developed over a period of weeks, resulting in higher doses being needed to achieve the same effects. Withdrawal symptoms, including aches and pains, restlessness, nausea, anxiety, diarrhea, fever, headaches, runny nose, tremors, sweating, vomiting, and trouble sleeping, may be experienced by those ceasing use after regular and especially high-dose use.  Long Term Health Problems #  Long Term Health Problems Summary Needed.  Risk of Death #                       Context:                      This excerpt covers contraindications, hypersensitive individuals, drug abuse history, and addiction potential related to oxycodone, as outlined in the full medication profile. It provides critical safety information essential for understanding risks and precautions associated with oxycodone use.                  …\n",
      "\n",
      "Tweet  198  |  Chunk 0  |  score=0.0221\n",
      "--------------------------------------------------------------------------------\n",
      "Drug: Codeine | cid: 5284371 Source: psychonaut | Source description: Codeine (also known as 3-Methylmorphine) is a naturally-occurring opioid substance of the morphinan class found in extracts of the poppy, particularly Papaver bracteatum.[3] Members of this group produce effects such as sedation, cough suppression, and euphoria when administered.                      Text:                      Always conduct independent research (e.g. Google, DuckDuckGo, PubMed) to ensure that a combination of two or more substances is safe to consume. Some of the listed interactions have been sourced from TripSit.  Alcohol - Both substances potentiate the ataxia and sedation caused by the other and can lead to unexpected loss of consciousness at high doses. Place affected patients in the recovery position to prevent vomit aspiration from excess. Memory blackouts are likely  Stimulants - Stimulants increase respiration rate which allows for a higher dose of opiates than would otherwise be used. If the stimulant wears off first then the opiate may overcome the user and cause respiratory arrest.                       Context:                      This excerpt provides harm reduction information on dangerous drug interactions involving codeine, highlighting risks when combining opioids with substances like alcohol and stimulants. It emphasizes the importance of independent research before polydrug use and details specific interaction effects such as increased sedation and respiratory risks, making it essential for users seeking safe practices outlined in the full document.                  …\n",
      "\n",
      "Tweet  202  |  Chunk 0  |  score=0.0296\n",
      "--------------------------------------------------------------------------------\n",
      "Drug: Codeine | cid: 5284371 Source: psychonaut | Source description: Codeine (also known as 3-Methylmorphine) is a naturally-occurring opioid substance of the morphinan class found in extracts of the poppy, particularly Papaver bracteatum.[3] Members of this group produce effects such as sedation, cough suppression, and euphoria when administered.                      Text:                      Denmark: In Denmark, codeine is sold over the counter with max 9.6 mg in the mixture. The item is given over the counter, with no prescriptions. The strongest available over the counter preparation containing codeine has 9.6 mg (with aspirin, brand name Kodimagnyl); anything stronger requires a prescription for legal possession.[citation needed]  Finland: In Finland, codeine cough syrups with a maximum strength of 1mg/ml is sold in pharmacies over the counter. Codeine isn't available in pill form without a prescription. Any stronger cough syrup and combination painkillers (codeine with paracetamol or ibuprofen such as Panacod, Co-codamol, and Ardinex) require a prescription.[citation needed]                       Context:                      This section details the legal status and regulation of codeine in Denmark and Finland, highlighting their over-the-counter availability limits and prescription requirements. It provides specific information on maximum dosages and forms available without prescription, relevant to understanding regional drug laws and harm reduction considerations.                  …\n",
      "\n",
      "Tweet  202  |  Chunk 1  |  score=0.0290\n",
      "--------------------------------------------------------------------------------\n",
      "Drug: Codeine | cid: 5284371 Source: psychonaut | Source description: Codeine (also known as 3-Methylmorphine) is a naturally-occurring opioid substance of the morphinan class found in extracts of the poppy, particularly Papaver bracteatum.[3] Members of this group produce effects such as sedation, cough suppression, and euphoria when administered.                      Text:                      Erowid Experience Vaults: Codeine  Common forms  Codeine is available within pharmacies across the world in a variety of forms that combine it with other products that are dangerous or even fatal to consume at higher dosages. This is done to act as a deterrent to prevent their recreational use but can easily be circumvented with the use of a cold water extraction.    Co-codamol contain 500mg of paracetamol per 8mg of codeine. It is available behind the counter in any British pharmacy.    Nurofen plus contain 12.8mg of codeine alongside ibuprofen. It is available behind the counter in any British pharmacy. Due to the higher codeine content than co-codamol, they are better for cold water extraction.    Many prescription-strength cough syrups contain codeine and promethazine - an antihistamine. When used recreationally they are commonly known as lean or purple drank.  Toxicity and harm potential                       Context:                      This section details the common forms and preparations of codeine available worldwide, including over-the-counter medications like co-codamol and Nurofen Plus, as well as prescription cough syrups mixed with promethazine. It emphasizes the potential dangers of combining these formulations at high doses and provides insight into their recreational use and associated risks, complementing the broader discussion of codeine's effects, toxicity, and harm potential.                  …\n",
      "\n",
      "Tweet  202  |  Chunk 2  |  score=0.0272\n",
      "--------------------------------------------------------------------------------\n",
      "Drug: Codeine | cid: 5284371 Source: erowid | Source description: Frequently Asked Questions about Codeine Erowid name: codeine Category: PHARMS Field: FAQ                      Text:                      get many of the adverse effects associated with codeine but little euphoria. If codeine just doesn't work for you, this may be why. Some drugs also interfere with cyp2d6. Prime among these are the SSRIs, with the exception of Zoloft (if I remember correctly). The most potent inhibitor is paroxetine (paxil), followed by fluoxetine (prozac). If you are taking an SSRI, you will probably experience a markedly decreased euphoria when using codeine. (Paxil has a half life of only 24hrs, so not taking it for a few days will do miracles; the half life of prozac is 7 days.) Finally, codeine itself is a cyp2d6 inhibitor. This means that taking the whole dose as quickly as possible will probably give you the biggest high (ie. its a waste to redose in 30 mins). *GLUTHETHIMIDE A combination of codeine and gluthethimide (a sleeping agent) has been used in some places as a heroin substitute. Gluthethimide is an enzyme-inducer, and it allows the body to convert more than 10% of codeine into morphine.                       Context:                      This excerpt explains factors affecting codeine's effectiveness and euphoria, highlighting how certain drugs like SSRIs (especially paroxetine and fluoxetine) can interfere with CYP2D6 enzymatic conversion of codeine to morphine, reducing its psychoactive effects. It also mentions that codeine is a CYP2D6 inhibitor and describes the use of gluthethimide combined with codeine to enhance morphine conversion, relevant to sections on pharmacology and drug interactions within the full document.                  …\n",
      "\n",
      "Tweet  226  |  Chunk 0  |  score=0.0414\n",
      "--------------------------------------------------------------------------------\n",
      "Drug: Codeine | cid: 5284371 Source: psychonaut | Source description: Codeine (also known as 3-Methylmorphine) is a naturally-occurring opioid substance of the morphinan class found in extracts of the poppy, particularly Papaver bracteatum.[3] Members of this group produce effects such as sedation, cough suppression, and euphoria when administered.                      Text:                      United Kingdom: Under the Misuse of Drugs Act 1971 codeine is a Class B controlled substance or a Class A drug when prepared for injection.[24] The possession of controlled substances without a prescription is a criminal offense.[25] However, certain preparations of codeine are exempt from this restriction under Schedule 5 of the Misuse of Drugs Regulations 2001. It is thus legal to possess codeine without a prescription, provided that it is compounded with at least one other active or inactive ingredient and that the dosage of each tablet, capsule, etc does not exceed 100 mg or 2.5% concentration in the case of liquid preparations.[citation needed]                       Context:                      This section details the legal status of codeine in the United Kingdom, explaining its classification under the Misuse of Drugs Act 1971 and specific exemptions under Schedule 5 of the Misuse of Drugs Regulations 2001. It highlights the conditions under which possessing and using codeine without a prescription is permitted, including dosage and formulation limits. This legal overview is essential for understanding the regulatory framework surrounding codeine use and distribution in the UK.                  …\n",
      "\n",
      "Tweet  251  |  Chunk 2  |  score=0.0457\n",
      "--------------------------------------------------------------------------------\n",
      "Drug: Unknown | cid: N/A Source: psychonaut_CSV | Source description: ?                      Text:                      Infobox: Codeine | Chemical Nomenclature | Common names | Codeine, Lean, Purple Drank, Syrup | Substitutive name | 3-methylmorphine | Systematic name | (5α,6α)-7,8-Didehydro-4,5-epoxy-3-methoxy-17-methylmorphinan-6-ol | Class Membership | Psychoactive class | Opioid | Chemical class | Morphinan | Routes of Administration | WARNING: | Always start with lower doses due to differences between individual body weight, tolerance, metabolism, and personal sensitivity. | See responsible use section | . | ⇣ | Smoked | Dosage | Bioavailability | 49.9 - 59.7% | [2] | Duration | ⇣ | Oral | Dosage | Threshold | 30 mg | Light | 50 - 100 mg | Common | 100 - 150 mg | Strong | 150 - 200 mg | Heavy | 200 mg + | Duration | Total | 3 - 6 hours | Onset | 30 - 45 minutes | Come up | 1 - 2 hours | Peak | 3 - 5 hours | Offset | 2 - 4 hours | DISCLAIMER | : | PW's | dosage | information is gathered from users and | resources | for educational purposes only. It is not a recommendation and should be verified                       Context:                      This chunk provides detailed infobox metadata for codeine, including chemical names, common slang, dosage information, routes of administration, bioavailability, duration, and legal warnings. It complements the main text by summarizing key pharmacological and usage data critical for understanding codeine's properties, effects, and responsible use. This structured overview enhances quick reference and search retrieval for technical and safety-related information about codeine.                  …\n",
      "\n",
      "Tweet  321  |  Chunk 2  |  score=0.0420\n",
      "--------------------------------------------------------------------------------\n",
      "Drug: Codeine | cid: 5284371 Source: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.                      Text:                      Deaths related to opioid toxicity have increased in the past decades, and a significant proportion of the increase derives from accidental overdoses. Opioid overdose is characteristically associated with a triad of abnormally slow respiration (apnea), decreased consciousness (coma), and pinpoint pupils (miosis). Codeine has a narrow therapeutic index, with a dose of 500 to 1000 mg usually proving fatal, though codeine-dependent individuals have been reported to use as much as 1536 mg daily.                       Context:                      This excerpt provides critical information on the toxicity and overdose risks of codeine, highlighting the increasing prevalence of opioid-related deaths and the narrow margin between therapeutic and fatal doses. It emphasizes the clinical triad of opioid overdose symptoms—respiratory depression, decreased consciousness, and pinpoint pupils—and notes that doses as high as 1536 mg can be lethal for dependent individuals. This content is essential for understanding the safety profile and toxicological concerns of codeine within the broader scope of its pharmacology and safety hazards.                  …\n",
      "\n",
      "Tweet  333  |  Chunk 0  |  score=0.0224\n",
      "--------------------------------------------------------------------------------\n",
      "Drug: CBD | cid: 644019 Source: psychonaut | Source description: Cannabidiol (also known as CBD and Epidiolex®) is a naturally-occurring cannabinoid found in the cannabis plant. It is one of some 113 identified cannabinoids in cannabis plants, accounting for up to 40% of the plant's extract.[1] It does not possess the same psychoactivity as tetrahydrocannabinol (THC), which is responsible for the euphoric and hallucinogenic aspects of cannabis, and is typically described as non-intoxicating.                      Text:                      Legal status  Internationally, cannabidiol is not scheduled under the Convention on Psychotropic Substances or any other UN drug treaty.  Australia: Cannabidiol (in preparations for therapeutic use containing 2 per cent or less of other cannabinoids found in cannabis) was placed in Schedule 4 as a \"Prescription Only Medicine OR Prescription Animal Remedy\" in 2015. It was previously listed in Schedule 9 as a prohibited substance.[31]  Canada: Cannabidiol is specifically listed in the Schedule II Controlled Drugs and Substances Act. However, in 2016 Canada’s \"Access to Cannabis for Medical Purposes Regulations\" came into effect. These regulations improve access to cannabis used for medicinal purposes, including CBD.[32]  Hong Kong: Illegal in Hong Kong since 1st February 2023, punishable by 7 years imprisonment.[33]                       Context:                      This section provides an overview of the international and national legal statuses of cannabidiol (CBD), detailing its scheduling and legal restrictions in various countries. It highlights regions where CBD is legal, regulated, or illegal, and specifies recent changes in jurisdictions like Australia, Canada, and Hong Kong. This information is crucial for understanding the legal considerations associated with CBD use and distribution worldwide.                  …\n",
      "\n",
      "Tweet  343  |  Chunk 0  |  score=0.0355\n",
      "--------------------------------------------------------------------------------\n",
      "Drug: MDMA | cid: 1615 Source: pubchem | Source description: 3,4-Methylenedioxymethamphetamine | C11H15NO2 | CID 1615 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.                      Text:                      OLSON, K.R. (Ed). Poisoning and Drug Overdose, Sixth Edition. McGraw-Hill, New York, NY 2012, p. 79  12.1.5 Human Toxicity Excerpts  /HUMAN EXPOSURE STUDIES/ A comprehensive cognitive test battery was administered to 28 abstinent ecstasy users with concomitant use of cannabis only and to two equally sized matched groups of cannabis users and non-users. The sample consisted of ecstasy users with a typical recreational use pattern and did not include very heavy users. Ecstasy users were unimpaired in simple tests of attention (alertness). However, they performed worse than one or both control groups in the more complex tests of attention, in memory and learning tasks, and in tasks reflecting aspects of general intelligence. Heavier ecstasy and heavier cannabis use were associated with poorer performance in the group of ecstasy users. By contrast, the cannabis users did not differ significantly in their performance from the non-users.  PMID:10811690                       Context:                      This section summarizes human toxicity research, specifically a study assessing cognitive performance among abstinent ecstasy users compared to controls, highlighting that typical recreational ecstasy use may impair complex attention, memory, and intelligence tasks. It is relevant within the broader document providing comprehensive information on MDMA's pharmacology, toxicity, and adverse effects, offering specific evidence of cognitive risks associated with recreational use. Key details include the sample size, use patterns, and distinction between light and heavy use impacts.                  …\n",
      "\n",
      "Tweet  343  |  Chunk 1  |  score=0.0355\n",
      "--------------------------------------------------------------------------------\n",
      "Drug: MDMA | cid: 1615 Source: pubchem | Source description: 3,4-Methylenedioxymethamphetamine | C11H15NO2 | CID 1615 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.                      Text:                      OLSON, K.R. (Ed). Poisoning and Drug Overdose, Sixth Edition. McGraw-Hill, New York, NY 2012, p. 79  12.1.5 Human Toxicity Excerpts  /HUMAN EXPOSURE STUDIES/ A comprehensive cognitive test battery was administered to 28 abstinent ecstasy users with concomitant use of cannabis only and to two equally sized matched groups of cannabis users and non-users. The sample consisted of ecstasy users with a typical recreational use pattern and did not include very heavy users. Ecstasy users were unimpaired in simple tests of attention (alertness). However, they performed worse than one or both control groups in the more complex tests of attention, in memory and learning tasks, and in tasks reflecting aspects of general intelligence. Heavier ecstasy and heavier cannabis use were associated with poorer performance in the group of ecstasy users. By contrast, the cannabis users did not differ significantly in their performance from the non-users.  PMID:10811690                       Context:                      This section summarizes human toxicity research, specifically a study assessing cognitive performance among abstinent ecstasy users compared to controls, highlighting that typical recreational ecstasy use may impair complex attention, memory, and intelligence tasks. It is relevant within the broader document providing comprehensive information on MDMA's pharmacology, toxicity, and adverse effects, offering specific evidence of cognitive risks associated with recreational use. Key details include the sample size, use patterns, and distinction between light and heavy use impacts.                  …\n",
      "\n",
      "Tweet  430  |  Chunk 0  |  score=0.0263\n",
      "--------------------------------------------------------------------------------\n",
      "Drug: CBD | cid: 644019 Source: psychonaut | Source description: Cannabidiol (also known as CBD and Epidiolex®) is a naturally-occurring cannabinoid found in the cannabis plant. It is one of some 113 identified cannabinoids in cannabis plants, accounting for up to 40% of the plant's extract.[1] It does not possess the same psychoactivity as tetrahydrocannabinol (THC), which is responsible for the euphoric and hallucinogenic aspects of cannabis, and is typically described as non-intoxicating.                      Text:                      ↑ Angell, T. (2018), UN Launches First-Ever Full Review Of Marijuana’s Status Under International Law  ↑ Iffland, Kerstin; Grotenhermen, Franjo (2017). \"An Update on Safety and Side Effects of Cannabidiol: A Review of Clinical Data and Relevant Animal Studies\". Cannabis and Cannabinoid Research. 2 (1): 139–154. doi:10.1089/can.2016.0034. ISSN 2378-8763.  ↑ 7.0 7.1 Mechoulam, R., Hanuš, L. (December 2002). \"Cannabidiol: an overview of some chemical and pharmacological aspects. Part I: chemical aspects\". Chemistry and Physics of Lipids. 121 (1–2): 35–43. doi:10.1016/S0009-3084(02)00144-5. ISSN 0009-3084.  ↑ How the Associated Press collected information on CBD vapes, 2019  ↑ Sharma, P., Murthy, P., Bharath, M. M. S. (2012). \"Chemistry, metabolism, and toxicology of cannabis: clinical implications\". Iranian Journal of Psychiatry. 7 (4): 149–156. ISSN 1735-4587.                       Context:                      This excerpt lists key academic and industry references related to cannabidiol (CBD), including scholarly reviews on its safety and side effects, chemical properties, and research developments, providing authoritative sources within the broader comprehensive overview of CBD covered in the full webpage content.                  …\n",
      "\n",
      "Tweet  477  |  Chunk 1  |  score=0.0267\n",
      "--------------------------------------------------------------------------------\n",
      "Drug: Morphine | cid: 5288826 Source: psychonaut | Source description: Morphine is a naturally-occurring opioid substance of the morphinan class. It is one of the natural plant alkaloids found in opium, along side codeine which is extracted from Papaver somniferum (also known as the poppy plant).[6] Additionally, it is considered to be the prototype opiate (i.e. the standard to which others are compared) and the basis of derivatives such as codeine, diacetylmorphine (heroin), and hydrocodone.                      Text:                      Friswell J, Phillips C, Holding J, Morgan CJ, Brandner B, Curran HV (2008). Acute effects of opioids on memory functions of healthy men and women. Psychopharmacology (Berl.). 198 (2): 243–50. https://doi.org/10.1007/s00213-008-1123-x.  Stefano GB, Ptáček R, Kuželová H, Kream RM (2012). Endogenous morphine: up-to-date review (2011). Folia Biol. (Praha). 58 (2): 49–56. PMID 22578954. Positive evolutionary pressure has apparently preserved the ability to synthesize chemically authentic morphine, albeit in homeopathic concentrations, throughout animal phyla.  References  ↑ Risks of Combining Depressants - TripSit  ↑ \"Medsafe (PDF)  ↑ \"FDA (PDF)  ↑ \"South Australian Neonatal Medication Guidelines (PDF)  ↑ \"Pfizer  ↑ Dicpinigaitis, P. V., Morice, A. H., Birring, S. S., McGarvey, L., Smith, J. A., Canning, B. J., Page, C. P. (April 2014). Sibley, D. R., ed. \"Antitussive Drugs—Past, Present, and Future\". Pharmacological Reviews. 66 (2): 468–512. doi:10.1124/pr.111.005116. ISSN 0031-6997.                       Context:                      This excerpt lists key scientific references related to the pharmacological effects and biological properties of opioids and endogenous morphine, complementing the overall document's detailed discussion of morphine's effects, pharmacology, and harm potential. These studies provide research backing for sections on opioid memory impacts and endogenous morphine production across species, enhancing the reference framework of the webpage.                  …\n",
      "\n",
      "Tweet  547  |  Chunk 1  |  score=0.0382\n",
      "--------------------------------------------------------------------------------\n",
      "Drug: Codeine | cid: 5284371 Source: psychonaut | Source description: Codeine (also known as 3-Methylmorphine) is a naturally-occurring opioid substance of the morphinan class found in extracts of the poppy, particularly Papaver bracteatum.[3] Members of this group produce effects such as sedation, cough suppression, and euphoria when administered.                      Text:                      Compulsive redosing - It is worth noting that redosing codeine will not amplify the intensity of its effects.  Dream potentiation  Sleepiness  Visual effects  Eye.svg  Suppressions  Double vision - At high doses, the eyes un-focus and re-focus uncontrollably. This creates a blurred effect and double vision that is present no matter where one focuses their eyes. This can be so intense it becomes impossible to read or drive.  Hallucinatory States  Internal Hallucination -One may experience a state of semi-consciousness and hypnagogia during heavy dosage nodding which results in dream-like states and up to level 3 imagery. This is often accompanied by ill-defined geometry.  Experience reports  There are currently no anecdotal reports which describe the effects of this compound within our experience index. Additional experience reports can be found here:  Erowid Experience Vaults: Codeine  Common forms                       Context:                      This section details the subjective effects and visual/hallucinatory experiences associated with codeine, including phenomena like double vision, internal hallucinations, and dream-like states. It also notes that redosing does not increase effects and references anecdotal experience reports, providing insight into the drug's perceptual and cognitive impact within the broader harm reduction and effects overview.                  …\n",
      "\n",
      "Tweet  571  |  Chunk 2  |  score=0.0251\n",
      "--------------------------------------------------------------------------------\n",
      "Drug: Morphine | cid: 5288826 Source: psychonaut | Source description: Morphine is a naturally-occurring opioid substance of the morphinan class. It is one of the natural plant alkaloids found in opium, along side codeine which is extracted from Papaver somniferum (also known as the poppy plant).[6] Additionally, it is considered to be the prototype opiate (i.e. the standard to which others are compared) and the basis of derivatives such as codeine, diacetylmorphine (heroin), and hydrocodone.                      Text:                      Friswell J, Phillips C, Holding J, Morgan CJ, Brandner B, Curran HV (2008). Acute effects of opioids on memory functions of healthy men and women. Psychopharmacology (Berl.). 198 (2): 243–50. https://doi.org/10.1007/s00213-008-1123-x.  Stefano GB, Ptáček R, Kuželová H, Kream RM (2012). Endogenous morphine: up-to-date review (2011). Folia Biol. (Praha). 58 (2): 49–56. PMID 22578954. Positive evolutionary pressure has apparently preserved the ability to synthesize chemically authentic morphine, albeit in homeopathic concentrations, throughout animal phyla.  References  ↑ Risks of Combining Depressants - TripSit  ↑ \"Medsafe (PDF)  ↑ \"FDA (PDF)  ↑ \"South Australian Neonatal Medication Guidelines (PDF)  ↑ \"Pfizer  ↑ Dicpinigaitis, P. V., Morice, A. H., Birring, S. S., McGarvey, L., Smith, J. A., Canning, B. J., Page, C. P. (April 2014). Sibley, D. R., ed. \"Antitussive Drugs—Past, Present, and Future\". Pharmacological Reviews. 66 (2): 468–512. doi:10.1124/pr.111.005116. ISSN 0031-6997.                       Context:                      This excerpt lists key scientific references related to the pharmacological effects and biological properties of opioids and endogenous morphine, complementing the overall document's detailed discussion of morphine's effects, pharmacology, and harm potential. These studies provide research backing for sections on opioid memory impacts and endogenous morphine production across species, enhancing the reference framework of the webpage.                  …\n",
      "\n",
      "Tweet  617  |  Chunk 1  |  score=0.0207\n",
      "--------------------------------------------------------------------------------\n",
      "Drug: Methamphetamine | cid: 10836 Source: erowid | Source description: A summary of basic information about Methamphetamine and its use. Erowid name: meth Category: CHEMICALS Field: Basics                      Text:                      Duration #  4-8 hours when smoked.  Visual Effects #  Visuals Summary Needed.  PROBLEMS #  Methamphetamine use generally increases the heart rate, blood pressure, body temperature, and rate of breathing of the user. Chronic use can lead to what is called 'Amphetamine Psychosis', resulting in paranoia, auditory and visual hallucinations, self-absorption, irritability, aggressive and erratic behavior, and picking at the skin. This can be magnified by lack of sleep which often accompanies heavy use of meth. Methamphetamine is an anorexant, meaning it causes most people to lose interest in food. This is considered a benefit for many light users, but in regular or heavy users can lead to malnutrition. Methamphetamine is also believed to be neurotoxic.  Contraindications #                       Context:                      This excerpt provides key information about the effects, problems, and contraindications associated with methamphetamine use, including duration, visual effects, health risks, and safety warnings. It is relevant for understanding the substance's pharmacological profile and potential dangers within the comprehensive Erowid drug information database.                  …\n",
      "\n",
      "Tweet  634  |  Chunk 0  |  score=0.0445\n",
      "--------------------------------------------------------------------------------\n",
      "Drug: Morphine | cid: 5288826 Source: psychonaut | Source description: Morphine is a naturally-occurring opioid substance of the morphinan class. It is one of the natural plant alkaloids found in opium, along side codeine which is extracted from Papaver somniferum (also known as the poppy plant).[6] Additionally, it is considered to be the prototype opiate (i.e. the standard to which others are compared) and the basis of derivatives such as codeine, diacetylmorphine (heroin), and hydrocodone.                      Text:                      Physical effects  Sedation  Physical euphoria - The physical euphoria experienced on this substance is extremely intense when compared to other opioids such as codeine or tramadol. The sensation itself can be described as feelings of intense physical comfort, warmth, love and bliss.  Muscle relaxation  Constipation  Cough suppression  Decreased libido  Difficulty urinating  Itchiness  Nausea  Pain relief - Many report that they are still aware of pain, however the pain is no longer of interest.  Pupil constriction  Respiratory depression  Skin flushing  Appetite suppression  Orgasm suppression  Cognitive effects  Cognitive euphoria - Morphine produces cognitive euphoria that is substantially stronger compared to other opioids such as codeine or tramadol, but weaker than that of heroin, hydrocodone, and oxycodone. The sensation can be described as powerful and all-encompassing feelings of emotional bliss, contentment, and happiness.  Anxiety suppression  Thought deceleration                       Context:                      This section details the physical and cognitive effects of morphine, including sensations of euphoria, muscle relaxation, pain relief, and side effects such as pupil constriction and respiratory depression. It provides a comprehensive overview of how morphine influences bodily functions and mental states, essential for understanding its subjective impact and harm potential in the full drug profile.                  …\n",
      "\n",
      "Tweet  638  |  Chunk 0  |  score=0.0234\n",
      "--------------------------------------------------------------------------------\n",
      "Drug: Morphine | cid: 5288826 Source: pubchem | Source description: Morphine | C17H19NO3 | CID 5288826 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.                      Text:                      is more commonly reported in those who are taking a drug like heroin or who are using prescribed pain medications in greater amounts or for longer than recommended by their healthcare provider. Use of an opioid close to the time of delivery can result in withdrawal symptoms in the baby (see the section of this fact sheet on Neonatal Abstinence Syndrome).                       Context:                      This excerpt discusses maternal opioid use during pregnancy, highlighting that higher doses or prolonged use—especially with drugs like heroin or prescribed pain medications—may increase risks such as neonatal withdrawal symptoms (Neonatal Abstinence Syndrome). Its relevance lies in the document's comprehensive coverage of morphine's pharmacology, safety, and pregnancy-related effects, providing critical information for healthcare providers and researchers on opioid exposure risks during childbirth.                  …\n",
      "\n",
      "Tweet  659  |  Chunk 0  |  score=0.0203\n",
      "--------------------------------------------------------------------------------\n",
      "Drug: Unknown | cid: N/A Source: psychonaut_CSV | Source description: ?                      Text:                      - United Kingdom: Under the Misuse of Drugs Act 1971 codeine is a Class B controlled substance or a Class A drug when prepared for injection. [24] The possession of controlled substances without a prescription is a criminal offense. [25] However, certain preparations of codeine are exempt from this restriction under Schedule 5 of the Misuse of Drugs Regulations 2001. It is thus legal to possess codeine without a prescription, provided that it is compounded with at least one other active or inactive ingredient and that the dosage of each tablet, capsule, etc does not exceed 100 mg or 2.5% concentration in the case of liquid preparations. [ citation needed ]                       Context:                      This excerpt details the legal status and regulations surrounding opioid codeine in the United Kingdom, specifying its classification under the Misuse of Drugs Act 1971 and exceptions under Schedule 5 of the Misuse of Drugs Regulations 2001. It highlights the conditions under which possession without a prescription is legal, including dosage limits and formulation requirements. This information is crucial for understanding the legal framework and restrictions on recreational and medicinal use of codeine in the UK.                  …\n",
      "\n",
      "Tweet  679  |  Chunk 0  |  score=0.0243\n",
      "--------------------------------------------------------------------------------\n",
      "Drug: Naltrexone | cid: 5360515 Source: pubchem | Source description: Naltrexone | C20H23NO4 | CID 5360515 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.                      Text:                      Naltrexone should not be administered with thioridazine due to the risk of lethargy and somnolence.  Mainstreaming Addiction Treatment (MAT) Act  The Mainstreaming Addiction Treatment (MAT) Act provision updates federal guidelines to expand the availability of evidence-based treatment to address the opioid epidemic. The MAT Act empowers all health care providers with a standard controlled substance license to prescribe buprenorphine for opioid use disorder (OUD), just as they prescribe other essential medications. The MAT Act is intended to help destigmatize a standard of care for OUD and integrate substance use disorder treatment across healthcare settings.                       Context:                      This excerpt discusses drug interaction warnings and recent regulatory developments related to naltrexone. It highlights a specific contraindication with thioridazine due to safety risks and provides an overview of the Mainstreaming Addiction Treatment (MAT) Act, which aims to expand access to opioid use disorder treatments by broadening provider prescribing rights for medications like buprenorphine. This information is relevant for understanding safety precautions and evolving policies surrounding naltrexone and related therapies.                  …\n",
      "\n",
      "Tweet  679  |  Chunk 1  |  score=0.0243\n",
      "--------------------------------------------------------------------------------\n",
      "Drug: Naltrexone | cid: 5360515 Source: pubchem | Source description: Naltrexone | C20H23NO4 | CID 5360515 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.                      Text:                      Naltrexone should not be administered with thioridazine due to the risk of lethargy and somnolence.  Mainstreaming Addiction Treatment (MAT) Act  The Mainstreaming Addiction Treatment (MAT) Act provision updates federal guidelines to expand the availability of evidence-based treatment to address the opioid epidemic. The MAT Act empowers all health care providers with a standard controlled substance license to prescribe buprenorphine for opioid use disorder (OUD), just as they prescribe other essential medications. The MAT Act is intended to help destigmatize a standard of care for OUD and integrate substance use disorder treatment across healthcare settings.                       Context:                      This excerpt discusses drug interaction warnings and recent regulatory developments related to naltrexone. It highlights a specific contraindication with thioridazine due to safety risks and provides an overview of the Mainstreaming Addiction Treatment (MAT) Act, which aims to expand access to opioid use disorder treatments by broadening provider prescribing rights for medications like buprenorphine. This information is relevant for understanding safety precautions and evolving policies surrounding naltrexone and related therapies.                  …\n",
      "\n",
      "Tweet  686  |  Chunk 0  |  score=0.0481\n",
      "--------------------------------------------------------------------------------\n",
      "Drug: Fentanyl | cid: 3345 Source: pubchem | Source description: Fentanyl | C22H28N2O | CID 3345 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.                      Text:                      7.17 Drug Tolerance  In opiate-naive (nontolerant) patients, minimum effective analgesic serum fentanyl concentrations range from 0.2-2 ng/mL. Adverse effects of the drug in opiate-naive patients generally increase as serum concentrations exceed 2 ng/mL, although respiratory depression (e.g., hypoventilation) can occur throughout the therapeutic range of fentanyl serum concentrations, especially in patients with underlying pulmonary conditions or those receiving concomitant therapy with respiratory depressants. CNS depression becomes prominent as serum fentanyl concentrations exceed 3 ng/mL in opiate-naive patients, and anesthesia and profound respiratory depression generally occur at concentrations of 10-20 ng/mL. With continued use, tolerance to the pharmacologic and adverse effects of the drug develop, but the rate of development of tolerance exhibits considerable interindividual variation.                       Context:                      This section discusses fentanyl drug tolerance, highlighting serum concentration ranges linked to analgesic effectiveness and adverse effects, including respiratory depression and CNS depression, in opiate-naive patients. It emphasizes the development of tolerance with continued use and the variability in individual responses, making it relevant for understanding fentanyl's pharmacodynamics and safety profile within the comprehensive drug information document.                  …\n",
      "\n",
      "Tweet  742  |  Chunk 0  |  score=0.0225\n",
      "--------------------------------------------------------------------------------\n",
      "Drug: Morphine | cid: 5288826 Source: psychonaut | Source description: Morphine is a naturally-occurring opioid substance of the morphinan class. It is one of the natural plant alkaloids found in opium, along side codeine which is extracted from Papaver somniferum (also known as the poppy plant).[6] Additionally, it is considered to be the prototype opiate (i.e. the standard to which others are compared) and the basis of derivatives such as codeine, diacetylmorphine (heroin), and hydrocodone.                      Text:                      The risk of fatal opioid overdoses rise sharply after a period of cessation and relapse, largely because of reduced tolerance.[33] To account for this lack of tolerance, it is safer to only dose a fraction of one's usual dosage if relapsing. It has also been found that the environment one is in can play a role in opioid tolerance. In one scientific study, rats with the same history of heroin administration were significantly more likely to die after receiving their dose in an environment not associated with the drug in contrast to a familiar environment.[34]  Dangerous interactions  Morphine is dangerous to use in combination with other depressants as many fatalities reported as overdoses are caused by interactions with other depressant drugs like alcohol or benzodiazepines, resulting in dangerously high levels of respiratory depression.[35]                       Context:                      This excerpt discusses the dangers of opioid overdose, emphasizing how reduced tolerance after cessation increases overdose risk and how environmental factors influence this risk. It also highlights the heightened danger of combining morphine with other depressants like alcohol or benzodiazepines, which can lead to fatal respiratory depression. These points are crucial for understanding morphine's toxicity, overdose prevention, and harm reduction strategies detailed in the full document.                  …\n",
      "\n",
      "Tweet  760  |  Chunk 2  |  score=0.0338\n",
      "--------------------------------------------------------------------------------\n",
      "Drug: Morphine | cid: 5288826 Source: erowid | Source description: Information about Morphine including uses, images, dosage, effects, legal status, and links to other resources. Erowid name: morphine Category: PHARMS Field: MainPage                      Text:                      Hotel Bathroom Extravaganza, by Atonable Junky  To Hell and Back, by Morphina  Basic Morphine Prep and the Experience, by Drug Geek  On the Magickal Uses of Opioids, by Glozey  » » » MORE » » »  OFF-SITE RESOURCES  PRIMARY RESOURCES #  RxList : Morphine  UN ODC : Morphine  SECONDARY RESOURCES #  Morphine - Wikipedia.org  Morphine - TripSit.me  MEDIA COVERAGE #  Ending the agony: Access to morphine as an ethical and human rights imperative - IDPC, Apr 2018  'War on drugs means millions are needlessly dying in pain' - CNN, Nov 2015  Study: Fast Morphine Treatment May Prevent PTSD - NYTimes, Jan 2010  Morphine found to help stave off PTSD in wounded troops - Washington Post, Jan 2010  Morphine Apparently in Your Head - Wired, Sep 2004  HEALTH INFORMATION #  Avinza Time Release Label with new Alcohol Warnings - Nov 2005, FDA  GOVERNMENT ARTICLES #  Acess to Controlled Medicines around the World in 2011 - WHO  [ back to pharms ]  Created by Erowid - Feb 21, 2003 Modified - Jul 29, 2023                       Context:                      This section lists user experiences, media coverage, health information, and government resources related to morphine, providing additional context and external links within the Erowid pharmacology database. It enhances understanding of morphine's effects, legal status, and societal impact, making it valuable for research, harm reduction, and educational purposes.                  …\n",
      "\n",
      "Tweet  829  |  Chunk 0  |  score=0.0320\n",
      "--------------------------------------------------------------------------------\n",
      "Drug: Morphine | cid: 5288826 Source: erowid | Source description: Information on the legal status of morphine. Erowid name: morphine Category: PHARMS Field: Law                      Text:                      U.S. STATE LAW #  While most state laws are consistent with the federal scheduling system, they can and do vary from state to state. As most prosecutions happen at the state level it is important to be familiar with your state and local laws.  INTERNATIONAL LAW #  Canada #  Morphine is schedule I in Canada. (Note: Canadian schedules are very different than U.S. schedules)  Portugal #  Effective July 2001, personal use of morphine without a prescription was decriminalized by Law 30/2000 (see text of law). Possession of less than 2 g is not regarded as a criminal offense, though the substance is liable to be seized and the possessor can be referred to mandatory treatment. Sale, or possession of quantities greater than the personal possession limit, are criminal offenses punishable by jail time. (thanks P)  Russia #                       Context:                      This excerpt provides a summary of legal regulations regarding morphine at the U.S. state level and internationally, including Canada, Portugal, and Russia. It highlights variations between federal and local laws, decriminalization efforts, and jurisdiction-specific restrictions, making it essential for understanding legal considerations related to morphine use and possession.                  …\n",
      "\n",
      "Tweet  831  |  Chunk 0  |  score=0.0400\n",
      "--------------------------------------------------------------------------------\n",
      "Drug: Morphine | cid: 5288826 Source: psychonaut | Source description: Morphine is a naturally-occurring opioid substance of the morphinan class. It is one of the natural plant alkaloids found in opium, along side codeine which is extracted from Papaver somniferum (also known as the poppy plant).[6] Additionally, it is considered to be the prototype opiate (i.e. the standard to which others are compared) and the basis of derivatives such as codeine, diacetylmorphine (heroin), and hydrocodone.                      Text:                      Physical effects  Sedation  Physical euphoria - The physical euphoria experienced on this substance is extremely intense when compared to other opioids such as codeine or tramadol. The sensation itself can be described as feelings of intense physical comfort, warmth, love and bliss.  Muscle relaxation  Constipation  Cough suppression  Decreased libido  Difficulty urinating  Itchiness  Nausea  Pain relief - Many report that they are still aware of pain, however the pain is no longer of interest.  Pupil constriction  Respiratory depression  Skin flushing  Appetite suppression  Orgasm suppression  Cognitive effects  Cognitive euphoria - Morphine produces cognitive euphoria that is substantially stronger compared to other opioids such as codeine or tramadol, but weaker than that of heroin, hydrocodone, and oxycodone. The sensation can be described as powerful and all-encompassing feelings of emotional bliss, contentment, and happiness.  Anxiety suppression  Thought deceleration                       Context:                      This section details the physical and cognitive effects of morphine, including sensations of euphoria, muscle relaxation, pain relief, and side effects such as pupil constriction and respiratory depression. It provides a comprehensive overview of how morphine influences bodily functions and mental states, essential for understanding its subjective impact and harm potential in the full drug profile.                  …\n",
      "\n",
      "Tweet  831  |  Chunk 1  |  score=0.0400\n",
      "--------------------------------------------------------------------------------\n",
      "Drug: Morphine | cid: 5288826 Source: psychonaut | Source description: Morphine is a naturally-occurring opioid substance of the morphinan class. It is one of the natural plant alkaloids found in opium, along side codeine which is extracted from Papaver somniferum (also known as the poppy plant).[6] Additionally, it is considered to be the prototype opiate (i.e. the standard to which others are compared) and the basis of derivatives such as codeine, diacetylmorphine (heroin), and hydrocodone.                      Text:                      Physical effects  Sedation  Physical euphoria - The physical euphoria experienced on this substance is extremely intense when compared to other opioids such as codeine or tramadol. The sensation itself can be described as feelings of intense physical comfort, warmth, love and bliss.  Muscle relaxation  Constipation  Cough suppression  Decreased libido  Difficulty urinating  Itchiness  Nausea  Pain relief - Many report that they are still aware of pain, however the pain is no longer of interest.  Pupil constriction  Respiratory depression  Skin flushing  Appetite suppression  Orgasm suppression  Cognitive effects  Cognitive euphoria - Morphine produces cognitive euphoria that is substantially stronger compared to other opioids such as codeine or tramadol, but weaker than that of heroin, hydrocodone, and oxycodone. The sensation can be described as powerful and all-encompassing feelings of emotional bliss, contentment, and happiness.  Anxiety suppression  Thought deceleration                       Context:                      This section details the physical and cognitive effects of morphine, including sensations of euphoria, muscle relaxation, pain relief, and side effects such as pupil constriction and respiratory depression. It provides a comprehensive overview of how morphine influences bodily functions and mental states, essential for understanding its subjective impact and harm potential in the full drug profile.                  …\n",
      "\n",
      "Tweet  833  |  Chunk 2  |  score=0.0320\n",
      "--------------------------------------------------------------------------------\n",
      "Drug: Morphine | cid: 5288826 Source: pubchem | Source description: Morphine | C17H19NO3 | CID 5288826 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.                      Text:                      Company  ALPHARMA PHARMS  Date  10/7/19  7.6 WHO Essential Medicines  Drug  Drug Classes  Formulation  Indication  Drug  Morphine  Drug Classes  Opioid analgesics  Formulation  (1) Oral - Liquid: 10 mg per 5 mL (morphine hydrochloride or morphine sulfate); (2) Oral - Solid: 10 mg immediate release (morphine sulfate); 10 to 200 mg slow release (morphine hydrochloride or morphine sulfate); (3) Oral - Other: 20 to 200 mg slow release granules to mix with water (morphine sulfate); (4) Parenteral - General injections - unspecified: 10 mg in 1 mL ampoule (morphine hydrochloride or morphine sulfate)  Indication  Pain  Drug  Morphine  Drug Classes  Preoperative medication and sedation for short-term procedures  Formulation  Parenteral - General injections - IV: 10 mg in 1 mL ampoule (morphine hydrochloride or morphine sulfate)  Indication  Opioids or related analgesicsÂ and agents affecting opioid receptors  7.7 FDA Approved Drugs  7.8 FDA Orange Book  7.9 FDA National Drug Code Directory                       Context:                      This excerpt details the pharmaceutical formulations, approval status, and indications for morphine by AlphaPharma, including oral, injectable, and preoperative uses. It is part of the comprehensive chemical and medical classification information provided in the full webpage, relevant for understanding morphine's approved medical applications and regulatory status. The data supports research and regulatory searches relating to morphine’s medicinal and legal details.                  …\n",
      "\n",
      "Tweet  835  |  Chunk 1  |  score=0.0423\n",
      "--------------------------------------------------------------------------------\n",
      "Drug: Morphine | cid: 5288826 Source: psychonaut | Source description: Morphine is a naturally-occurring opioid substance of the morphinan class. It is one of the natural plant alkaloids found in opium, along side codeine which is extracted from Papaver somniferum (also known as the poppy plant).[6] Additionally, it is considered to be the prototype opiate (i.e. the standard to which others are compared) and the basis of derivatives such as codeine, diacetylmorphine (heroin), and hydrocodone.                      Text:                      Heavy dosages of morphine can result in respiratory depression, leading onto fatal or dangerous levels of anoxia (oxygen deprivation). This occurs because the breathing reflex is suppressed by agonism of µ-opioid receptors proportional to the dosage consumed.  Morphine can also cause nausea and vomiting; a significant number of deaths attributed to opioid overdose are caused by aspiration of vomit by an unconscious victim. This is when an unconscious or semi-conscious user who is lying on their back vomits into their mouth and unknowingly suffocates. It can be prevented by ensuring that one is lying on their side with their head tilted downwards so that the airways cannot be blocked in the event of vomiting while unconscious (also known as the recovery position).  It is strongly recommended that one use harm reduction practices when using this substance.  Dependence and abuse potential                       Context:                      This excerpt discusses the serious risks of overdose with morphine, including respiratory depression and death, and highlights the importance of harm reduction practices such as preventing aspiration by lying in the recovery position. It also introduces the drug's dependence and abuse potential, emphasizing safety considerations within the broader context of morphine's effects and toxicity.                  …\n",
      "\n",
      "Tweet  844  |  Chunk 0  |  score=0.0288\n",
      "--------------------------------------------------------------------------------\n",
      "Drug: Morphine | cid: 5288826 Source: erowid | Source description: Information about Morphine including uses, images, dosage, effects, legal status, and links to other resources. Erowid name: morphine Category: PHARMS Field: MainPage                      Text:                      Hotel Bathroom Extravaganza, by Atonable Junky  To Hell and Back, by Morphina  Basic Morphine Prep and the Experience, by Drug Geek  On the Magickal Uses of Opioids, by Glozey  » » » MORE » » »  OFF-SITE RESOURCES  PRIMARY RESOURCES #  RxList : Morphine  UN ODC : Morphine  SECONDARY RESOURCES #  Morphine - Wikipedia.org  Morphine - TripSit.me  MEDIA COVERAGE #  Ending the agony: Access to morphine as an ethical and human rights imperative - IDPC, Apr 2018  'War on drugs means millions are needlessly dying in pain' - CNN, Nov 2015  Study: Fast Morphine Treatment May Prevent PTSD - NYTimes, Jan 2010  Morphine found to help stave off PTSD in wounded troops - Washington Post, Jan 2010  Morphine Apparently in Your Head - Wired, Sep 2004  HEALTH INFORMATION #  Avinza Time Release Label with new Alcohol Warnings - Nov 2005, FDA  GOVERNMENT ARTICLES #  Acess to Controlled Medicines around the World in 2011 - WHO  [ back to pharms ]  Created by Erowid - Feb 21, 2003 Modified - Jul 29, 2023                       Context:                      This section lists user experiences, media coverage, health information, and government resources related to morphine, providing additional context and external links within the Erowid pharmacology database. It enhances understanding of morphine's effects, legal status, and societal impact, making it valuable for research, harm reduction, and educational purposes.                  …\n",
      "\n",
      "Tweet  881  |  Chunk 2  |  score=0.0206\n",
      "--------------------------------------------------------------------------------\n",
      "Drug: Fentanyl | cid: 3345 Source: pubchem | Source description: Fentanyl | C22H28N2O | CID 3345 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.                      Text:                      Actiq, C-II (Cephalon)  Route of Administration  Buccal (Transmucosal)  Dosage Form  Lozenge (solid drug matrix on a handle)  Strength  200 ug (of fentanyl)  Brand or Generic Form (Manufacturer)  Oral Transmucosal Fentanyl Citrate, C-II (Available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name)  Route of Administration  Buccal (Transmucosal)  Dosage Form  Lozenge (solid drug matrix on a handle)  Strength  400 ug (of fentanyl)  Brand or Generic Form (Manufacturer)  Actiq, C-II (Cephalon)  Route of Administration  Buccal (Transmucosal)  Dosage Form  Lozenge (solid drug matrix on a handle)  Strength  400 ug (of fentanyl)  Brand or Generic Form (Manufacturer)  Oral Transmucosal Fentanyl Citrate, C-II (Available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name)  Route of Administration  Buccal (Transmucosal)  Dosage Form  Lozenge (solid drug matrix on a handle)  Strength  600 ug (of fentanyl)                       Context:                      This excerpt details various formulations and strengths of buccal fentanyl lozenges, specifically Actiq (Cephalon), used for transmucosal administration. It provides dosage information (200-600 µg), multiple brand and manufacturer details, and highlights different strengths available, situating it within the broader context of fentanyl drug formulations and clinical use discussed in the full document.                  …\n",
      "\n",
      "Tweet  904  |  Chunk 2  |  score=0.0497\n",
      "--------------------------------------------------------------------------------\n",
      "Drug: Fentanyl | cid: 3345 Source: pubchem | Source description: Fentanyl | C22H28N2O | CID 3345 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.                      Text:                      Company  JANSSEN PHARMS  Date  3/4/21  7.5 WHO Essential Medicines  Drug  Drug Classes  Formulation  Indication  Drug  Fentanyl  Drug Classes  Opioid analgesics  Formulation  (1) Local - Topical - Transdermal patch: 12 Âµg/hour; 25 Âµg/hour; 50 Âµg/hour; 75 Âµg/hour; 100 Âµg/hour; (2) Oral - Solid: 100 to 800 Âµg sub-lingual tablet (as citrate); 200 to 1600 Âµg lozenge (as citrate); (3) Oral - Other: 200 to 1200 Âµg buccal film (as citrate)  Indication  (1) Chronic cancer pain; (2) Other specified chronic cancer related pain  7.6 FDA Approved Drugs  7.7 FDA Orange Book  7.8 FDA National Drug Code Directory  7.9 FDA Green Book  7.10 Drug Labels  Drug and label  Active ingredient and drug  7.11 Clinical Trials  7.11.1 ClinicalTrials.gov  7.11.2 EU Clinical Trials Register  7.11.3 NIPH Clinical Trials Search of Japan  7.12 DEA Drug and Chemical Information  Fentanyl  (Trade names:Actiq®, Fentora™, Duragesic®)  7.12.1 DEA Controlled Substances  1 of 3  Substance  Fentanyl                       Context:                      This chunk presents detailed information on Janssen Pharmaceutics' fentanyl product formulations, approval dates, and regulatory classifications, including WHO essential medicine status, FDA drug listings, and controlled substance scheduling. It is relevant for comprehensive drug identification, regulatory status, and formulation data within the full chemical profile of fentanyl, aiding in search retrieval of approved medical uses, formulations, and legal classifications. Key details include dosage forms, indications, and regulatory identifiers, supporting drug-specific queries.                  …\n",
      "\n",
      "\n",
      "Total chunks in [0.02, 0.05]: 37\n"
     ]
    }
   ],
   "source": [
    "################################################################################\n",
    "# Print every chunk whose relevance_score [0.02, 0.05]\n",
    "##############################################################################\n",
    "LOW, HIGH = 0.02, 0.05\n",
    "preview_chars = 30000\n",
    "\n",
    "count = 0\n",
    "for tweet_idx, tweet_chunks in enumerate(all_retrieved_chunks):\n",
    "    for chunk_idx, doc in enumerate(tweet_chunks):\n",
    "        score = doc.metadata.get(\"relevance_score\", 0.0)\n",
    "        if LOW <= score <= HIGH:\n",
    "            count += 1\n",
    "            print(f\"Tweet {tweet_idx:4d}  |  Chunk {chunk_idx}  |  score={score:.4f}\")\n",
    "            print(\"-\" * 80)\n",
    "            print(doc.page_content[:preview_chars].replace(\"\\n\", \" \") + \" …\")\n",
    "            print()\n",
    "\n",
    "print(f\"\\nTotal chunks in [{LOW}, {HIGH}]: {count:,}\")\n"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "86ff0a3f",
   "metadata": {},
   "source": [
    "# RUN 4 MODELS: rag_prompt"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "f39206c6",
   "metadata": {},
   "outputs": [],
   "source": [
    "\n",
    "# I settled with a threshold of 0.2\n",
    "THRESHOLD = 0.2\n",
    "\n",
    "def run_RAG_prompt_on_llm(get_funct, directory, prompt, tweets):\n",
    "    os.makedirs(f\"data/{directory}\", exist_ok=True)\n",
    "    responses = []\n",
    "    for i, row in tqdm(tweets.iterrows()):                          \n",
    "        text = row[\"text\"]\n",
    "        ######################################################################\n",
    "        # get the relevant chunks for this tweet\n",
    "        ########################################################################\n",
    "        retrieved_chunks = all_retrieved_chunks[i]\n",
    "        rag_chunks = ''\n",
    "        for chunk_idx, chunk in enumerate(retrieved_chunks):\n",
    "            score = chunk.metadata.get(\"relevance_score\")\n",
    "            if score >= THRESHOLD:\n",
    "                rag_chunks += chunk.page_content\n",
    "        #######################################################################\n",
    "        if rag_chunks != '': \n",
    "            i_prompt = (\n",
    "                prompt\n",
    "                .replace(\"{{rag_chunks}}\", rag_chunks)\n",
    "                .replace(\"{{tweet_text}}\", text)\n",
    "            )\n",
    "            response = get_funct(i_prompt)\n",
    "            # save each to file in data/directory\n",
    "            with open(f\"data/{directory}/{i}.json\", \"w\") as f:\n",
    "                f.write(response)\n",
    "            responses.append(response)\n",
    "    return responses"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 15,
   "id": "9787fcba",
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "0it [00:00, ?it/s]"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "747c153ca736459f8575fc18208404b0",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Loading checkpoint shards:   0%|          | 0/4 [00:00<?, ?it/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "1000it [22:11,  1.33s/it]\n",
      "0it [00:00, ?it/s]"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "75fe972fb53a49299a0b738c076f8b0d",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Loading checkpoint shards:   0%|          | 0/3 [00:00<?, ?it/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "1000it [41:48,  2.51s/it]\n"
     ]
    }
   ],
   "source": [
    "# o4-mini (smarter than GPT-4o-mini)\n",
    "responses = run_RAG_prompt_on_llm(get_openai_o4mini_response, \"o4mini_rag\", rag_prompt, tweets)\n",
    "\n",
    "# GPT-4o-mini\n",
    "responses = run_RAG_prompt_on_llm(get_openai_gpt4omini_response, \"gpt4omini_rag\", rag_prompt, tweets)\n",
    "\n",
    "# Meta-Llama-3.1-8B-Instruct\n",
    "responses = run_RAG_prompt_on_llm(get_llama_response, \"llama_rag\", rag_prompt, tweets)\n",
    "cleanup_llama()\n",
    "\n",
    "# Qwen-4B\n",
    "responses = run_RAG_prompt_on_llm(get_qwen_4b_response, \"qwen_4b_rag\", rag_prompt, tweets)\n",
    "cleanup_qwen_4b()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 19,
   "id": "6254c2bb",
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "1000it [00:00, 66014.61it/s]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "40\n",
      "40\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\n"
     ]
    }
   ],
   "source": [
    "THRESHOLD = 0.2\n",
    "def get_RAG_idxs(tweets):\n",
    "    RAG_idxs = []\n",
    "    for i, row in tqdm(tweets.iterrows()):                          \n",
    "        text = row[\"text\"]\n",
    "        ######################################################################\n",
    "        # get the relevant chunks for this tweet\n",
    "        ########################################################################\n",
    "        retrieved_chunks = all_retrieved_chunks[i]\n",
    "        rag_chunks = ''\n",
    "        for chunk_idx, chunk in enumerate(retrieved_chunks):\n",
    "            score = chunk.metadata.get(\"relevance_score\")\n",
    "            if score >= THRESHOLD:\n",
    "                rag_chunks += chunk.page_content\n",
    "        #######################################################################\n",
    "        if rag_chunks != '': \n",
    "            RAG_idxs.append(i)\n",
    "    print(len(RAG_idxs))\n",
    "    return RAG_idxs\n",
    "\n",
    "RAG_idxs = get_RAG_idxs(tweets)\n",
    "RAG_only_tweets = tweets.iloc[RAG_idxs].copy()\n",
    "print(len(RAG_only_tweets))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "7d7f2d27",
   "metadata": {},
   "outputs": [],
   "source": [
    ":)"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "llamafinetuning5",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.12.9"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
